I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes management guidelines focus on treatment individualization, including ethnic/cultural needs and risk of hypoglycemia and weight gain.\[[@ref1]\] Asian patients have higher postprandial glucose (PPG) levels compared with other regional groups\[[@ref2]\] and currently, a large proportion of Asian patients with type 2 diabetes (T2D) are treated with human premixed insulin.\[[@ref3]\] This review examines studies of efficacy and safety involving insulin analogs, biphasic insulin aspart 30 (BIAsp 30), and biphasic insulin lispro mix (LM 25/50).

D[IABETES:]{.smallcaps} A[N]{.smallcaps} E[VER-INCREASING]{.smallcaps} P[UBLIC]{.smallcaps} H[EALTH]{.smallcaps} B[URDEN]{.smallcaps} {#sec1-2}
=====================================================================================================================================

Globally, the number of people with diabetes continues to rise year on year, providing a major challenge to public health and an enormous economic burden.\[[@ref1][@ref4]\] The International Diabetes Federation estimates 382 million people globally had diabetes in 2013, with more than 160 million from China and India alone.\[[@ref4]\] T2D accounts for approximately 90% of all cases worldwide, and a worrying trend is the increasing diagnosis of T2D in children and adolescents.\[[@ref5]\]

In addition to economic development, rapid transitions to Western lifestyles, and increasing obesity rates,\[[@ref4][@ref6]\] other more inherent reasons might explain the escalating burden of T2D in regions such as Asia.\[[@ref2][@ref7][@ref8][@ref9][@ref10][@ref11]\] For example, in a study of healthy lean individuals, Asian patients had higher PPG levels and lower insulin sensitivity than Europeans in response to a 75 g carbohydrate load.\[[@ref2]\] A change in dietary patterns from traditional high-fiber, low-fat diets to Westernized diets (i.e. high intake of fats, carbohydrates, and trans-fatty acids) has been linked to postprandial hyperglycemia and hyperinsulinemia.\[[@ref11]\]

I[MPORTANCE OF]{.smallcaps} T[ARGETING]{.smallcaps} P[OSTPRANDIAL]{.smallcaps} G[LUCOSE]{.smallcaps} {#sec1-3}
====================================================================================================

While T2D therapy is directed toward lowering glycated hemoglobin (HbA1c) levels with emphasis on fasting plasma glucose (FPG), targeting PPG excursions is also important for achieving HbA1c goals.\[[@ref12]\] In T2D, the contribution of PPG toward total glycemic burden is enormous at any level of glycemic control. Furthermore, PPG contribution relative to FPG is greatest when HbA1c is \<7.5%,\[[@ref13]\] yet many patients experience significant PPG excursions even in the context of good glycemic control according to HbA1c and FPG.\[[@ref14][@ref15]\]

PPG elevations are detectable early in T2D progression.\[[@ref12]\] They result from loss of first-phase insulin secretion, decreased insulin sensitivity in peripheral tissues, and diminished suppression of hepatic glucose output after meals due to insulin insufficiency.\[[@ref12][@ref16]\] Since postprandial hyperglycemia is an earlier biochemical abnormality than fasting hyperglycemia,\[[@ref17]\] any treatment strategy addressing PPG may help to reduce the risk of complications.\[[@ref18]\] In the presence of insulin resistance, fasting insulin response is maintained in early T2D, while insulin response to meal-related hyperglycemia is inadequate,\[[@ref17]\] highlighting the importance of targeting PPG early in the disease course.\[[@ref18]\] Epidemiological study data have demonstrated a correlation between poor PPG control and development of cardiovascular disease,\[[@ref19]\] retinopathy, cognitive dysfunction, and cancer.\[[@ref12]\]

T[REATMENT]{.smallcaps} O[PTIONS:]{.smallcaps} R[ATIONALE FOR]{.smallcaps} P[REMIXED]{.smallcaps} I[NSULIN]{.smallcaps} {#sec1-4}
=======================================================================================================================

The progressive decline in β-cell function, which occurs years before T2D is diagnosed,\[[@ref20]\] means that many patients will eventually require insulin,\[[@ref1][@ref21]\] long considered the most effective antihyperglycemic medication available.\[[@ref22]\] Substantial barriers to initiating insulin include the fear of hypoglycemia and weight gain;\[[@ref23]\] it is therefore important to weigh glycemic benefits and hypoglycemia/weight gain risk when choosing an insulin regimen. There are three types of insulin therapy available for T2D: basal only, basal plus prandial (with premixed insulin or self-mixed basal--bolus insulin), and prandial only. While basal insulin is recommended in Europe and the USA, premixed insulin is the initial choice for 75% of South Asian patients\[[@ref24]\] and the most widely prescribed treatment in Asia.\[[@ref3]\] The simple nature of the regimen suits its use in primary care practice and in populations with different dietary habits and cultures; these constitute key reasons for its widespread use in Asia.\[[@ref3][@ref25][@ref26]\] Premixed insulins comprise basal and prandial insulins in one injection, making them convenient to administer. Treatment can be intensified from once (od) to 3 times daily (tid) and can be used in insulin-naive patients.\[[@ref27][@ref28]\]

L[ITERATURE]{.smallcaps} A[PPRAISAL]{.smallcaps} {#sec1-5}
================================================

This review summarizes randomized controlled trials (RCTs) and observational studies evaluating efficacy and safety of two commonly used premixed insulin analogs for T2D: BIAsp 30 and LM 25/50. A literature search was conducted using PubMed with the search terms "efficacy and safety of BIAsp odds ratio (OR) BIAsp in type 2 diabetes" and "efficacy and safety of biphasic insulin LM OR Humalog Mix in type 2 diabetes" over the past 10-year (as few citations were retrieved for BIAsp 30 vs. LM 25 with the 10 years filter, the literature analysis included one paper from 2002). The initial search returned 88 citations (BIAsp, 63; LM, 25). Articles were excluded if they evaluated only patient-reported outcomes, were *post hoc* analyses not relevant to the focus of this review, or they comparative studies with incretin mimetics. Cost-benefit analyses are important; however, the inclusion of these was beyond the scope of the current review. While insulin pump therapy is available in India,\[[@ref29]\] relevant studies are not discussed as neither BIAsp 30 nor LM 25/50 is approved for insulin pump use.

B[IPHASIC]{.smallcaps} I[NSULIN]{.smallcaps} A[SPART]{.smallcaps} 30 {#sec1-6}
====================================================================

BIAsp 30 comprises 30% soluble rapid-acting insulin aspart (IAsp; prandial component) and 70% intermediate-acting crystallized protamine-complexed IAsp (basal component).\[[@ref30]\] BIAsp 50 and BIAsp 70 are available for patients who require more prandial insulin; however, these formulations are not the focus of this review. BIAsp 30 is a well-established T2D treatment, available since 2002, which is associated with a wealth of clinical data from RCTs and observational studies of its efficacy and safety compared with other oral glucose-lowering therapies in a diverse range of patient populations.

O[VERVIEW OF]{.smallcaps} R[ANDOMIZED]{.smallcaps} C[ONTROLLED]{.smallcaps} T[RIALS OF]{.smallcaps} B[IPHASIC]{.smallcaps} I[NSULIN]{.smallcaps} A[SPART]{.smallcaps} 30 {#sec1-7}
========================================================================================================================================================================

Compared with basal and basal--bolus insulin regimens {#sec2-1}
-----------------------------------------------------

[Table 1](#T1){ref-type="table"} provides an overview of efficacy and safety data for BIAsp 30 compared with basal or basal--bolus insulin collated from 11 RCTs in patients of differing ethnicities.\[[@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39][@ref40]\] Notably, there tended to be greater HbA1c reductions in studies comparing BIAsp 30 and the basal insulin glargine in insulin-naive patients.\[[@ref31][@ref32][@ref33][@ref34]\] Yang *et al*. reported that BIAsp 30 was noninferior to glargine in an Asian population and demonstrated significantly lower PPG levels 2 h postmeal) without increased risk of hypoglycemia or weight gain.\[[@ref35]\] Comparisons of BIAsp 30 and basal--bolus regimens meanwhile showed similar (nonsignificant treatment-group differences) HbA1c reductions.\[[@ref38][@ref39]\]

###### 

Randomized controlled trials comparing biphasic insulin aspart 30 with (a) basal and (b) basal--bolus insulin regimens in type 2 diabetes

![](IJEM-20-288-g001)

As might be expected, greater reductions in glucose levels were associated with an increased risk of hypoglycemia (in all but one study).\[[@ref34]\] Where a significantly greater reduction in HbA1c was reported for BIAsp 30 than glargine, more patients experienced a hypoglycemic event (HE) (minor) or there was a greater relative risk of an event.\[[@ref31][@ref32][@ref33]\] In terms of change in body weight, BIAsp 30 and all comparators led to an increase from baseline, with no difference between study groups.\[[@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39][@ref40]\]

Compared with biphasic human insulin {#sec2-2}
------------------------------------

In all but one study, there was no significant difference in HbA1c between BIAsp 30 and biphasic human insulin (BHI) \[[Table 2](#T2){ref-type="table"}\].\[[@ref41][@ref42][@ref43][@ref44]\] In one single-center study of obese, insulin-naive patients with T2D, a significant difference in change in HbA1c from baseline favored BIAsp 30 combined with metformin at 3 months.\[[@ref45]\]

###### 

Randomized controlled trials comparing biphasic insulin aspart 30 and biphasic human insulin 30 in type 2 diabetes

![](IJEM-20-288-g002)

Significant differences favoring BIAsp 30 over BHI 30 were reported for PPG levels in the three studies evaluating this measure.\[[@ref42][@ref44][@ref46]\] In terms of safety, there were generally no treatment differences for weight change or hypoglycemia \[[Table 2](#T2){ref-type="table"}\]. An exception was a 24-month study, which demonstrated a significant reduction in year 2 with BIAsp 30 twice daily (bid) versus BHI 30 bid for major hypoglycemia.\[[@ref41]\] Also in terms of safety, a Japanese study found switching from BHI 30 to BIAsp 30 was associated with improved postprandial hyperglycemia (measured by 1,5-anhydroglucitol) and decreased cardio-ankle vascular index (a reflection of arterial stiffness).\[[@ref47]\]

Compared with oral glucose-lowering therapies {#sec2-3}
---------------------------------------------

Most of the studies comparing BIAsp 30 od, bid, or tid with oral antidiabetic drugs (OADs) reported a significant HbA1c reduction favoring premixed insulin regimens \[[Table 3](#T3){ref-type="table"}\].\[[@ref48][@ref49][@ref50][@ref51]\] These studies demonstrated additional benefits for BIAsp 30 over comparator OADs in terms of PPG levels \[[Table 3](#T3){ref-type="table"}\]. One study comparing BIAsp 30 bid with glibenclamide (both plus metformin) in patients uncontrolled on prior OADs demonstrated no treatment difference in glycemic control.\[[@ref52]\] Nevertheless, in a subgroup of patients with HbA1c ≥9% at baseline, BIAsp 30 was associated with significantly greater glycemic control than glibenclamide plus metformin (*P* \< 0.05).

###### 

Randomized controlled trials comparing biphasic insulin aspart 30 and oral glucose-lowering therapies in type 2 diabetes

![](IJEM-20-288-g003)

In general, few major HEs were reported for treatments; however, BIAsp treatment tended to be associated with more minor HEs.\[[@ref48][@ref49][@ref50][@ref51]\] Likewise, the effect on weight favored OADs, including glibenclamide plus metformin and metformin/pioglitazone, over BIAsp.\[[@ref49][@ref50][@ref51][@ref52]\]

O[VERVIEW OF]{.smallcaps} K[EY]{.smallcaps} O[BSERVATIONAL]{.smallcaps} S[TUDIES OF]{.smallcaps} B[IPHASIC]{.smallcaps} I[NSULIN]{.smallcaps} A[SPART]{.smallcaps} 30 {#sec1-8}
=====================================================================================================================================================================

While RCTs provide the most rigorous means of determining a cause-effect relationship between treatments and outcomes,\[[@ref53]\] observational, nonrandomized studies have an important and complementary role, allowing recruitment of larger patient cohorts in a setting more closely reflecting clinical practice. As such, they can help corroborate RCT results.

A number of such studies (i.e. IMPROVE\[[@ref54]\] and PRESENT\[[@ref55]\]) have examined the safety and effectiveness of BIAsp 30 across different countries and ethnicities. Collectively, these 6 months trials demonstrated improved glycemic control, as shown by reductions in HbA1c, FPG, and PPG levels from baseline, in patients initiating insulin with, or switching to, BIAsp 30.\[[@ref54][@ref55]\] Similar findings have been observed in the A~1~ chieve study, a prospective, multicenter, open-label, noninterventional, 24-week study of 66,726 patients from 30 countries across four continents, using insulin analogs (including BIAsp 30, insulin detemir, and IAsp).\[[@ref56]\] Numerous country-specific findings from A~1~ chieve have shown improvements from baseline to week 24 in HbA1c, PPG, hypoglycemia, and quality of life.\[[@ref57][@ref58][@ref59][@ref60]\]

B[IPHASIC]{.smallcaps} I[NSULIN]{.smallcaps} L[ISPRO]{.smallcaps} M[IX]{.smallcaps} 25/50 {#sec1-9}
=========================================================================================

LM 25 comprises 25% rapid-acting insulin lispro and 75% intermediate-acting insulin lispro protamine suspension. Also available is LM 50, which comprises 50% rapid-acting lispro and 50% lispro protamine suspension.\[[@ref61]\] Numerous reports from RCTs and observational studies, albeit fewer than recovered for BIAsp, demonstrate the efficacy and safety of LM 25 and LM 50 in T2D in Eastern and Western patient populations.\[[@ref62][@ref63][@ref64][@ref65][@ref66][@ref67][@ref68][@ref69][@ref70][@ref71]\] The following provides a brief review of findings for insulin-treated and insulin-naive patients.

O[VERVIEW OF]{.smallcaps} R[ANDOMIZED]{.smallcaps} C[ONTROLLED]{.smallcaps} T[RIALS OF]{.smallcaps} L[ISPRO]{.smallcaps} M[IX]{.smallcaps} 25/50 {#sec1-10}
================================================================================================================================================

Compared with basal and basal--bolus insulin regimens {#sec2-4}
-----------------------------------------------------

[Table 4](#T4){ref-type="table"} outlines key results of studies of LM 25 and LM 50 compared with basal or basal--bolus insulin regimens in patients uncontrolled on prior therapy with/without insulin. In studies comparing LM 25 or LM 50 with glargine, greater HbA1c reductions were reported, and PPG control was significantly improved with premixed insulin.\[[@ref62][@ref64][@ref66][@ref69]\] In the 24-week initiation phase of the Durability of Basal versus LM 75/25 Insulin Efficacy (DURABLE) study comparing LM 25 bid with glargine od, each in addition to OADs, LM 25 significantly decreased HbA1c and was associated with lower PPG levels after morning and evening meals.\[[@ref66]\] However, the incidence of hypoglycemia was significantly greater with LM 25, as was weight gain. In the maintenance phase of DURABLE, patients reaching target HbA1c ≤7.0% at the end of the 24-week initiation phase were monitored for up to an additional 24 months.\[[@ref68]\] This long-term follow-up showed a significantly greater proportion of patients treated with LM rather than insulin glargine maintained HbA1c goals and maintained goals for significantly longer. Furthermore, at study end, there was no difference between treatments regarding hypoglycemia and weight gain. In a recent *post hoc* analysis of DURABLE that examined the impact of race/ethnicity on the efficacy and safety of insulin regimens, significant differences were observed in the degree of reduction in HbA1c (smaller) and the proportion of patients reaching glycemic targets of \<7% (fewer) in Asian compared with Caucasian patients.\[[@ref71]\] Moreover, weight gain and rate of hypoglycemia were lower in Asian patients irrespective of treatment. These results demonstrate that racial/ethnic differences in outcomes are important considerations when designing insulin-based treatment plans.

###### 

Randomized controlled trials comparing lispro mix 25/lispro mix 50 with (a) basal and (b) basal--bolus insulin regimens in Type 2 diabetes

![](IJEM-20-288-g004)

Of three studies comparing LM 25 or LM 50 with glargine plus lispro, two showed no significant differences in HbA1c levels,\[[@ref67][@ref70]\] and one showed significantly better reduction with the basal--bolus regimen over LM 50 tid.\[[@ref63]\]

Compared with biphasic human insulin or oral glucose-lowering therapies {#sec2-5}
-----------------------------------------------------------------------

The literature search failed to retrieve any relevant publications assessing LM 25/LM 50 with BHI or with OADs.

O[VERVIEW OF]{.smallcaps} K[EY]{.smallcaps} O[BSERVATIONAL]{.smallcaps} S[TUDIES OF]{.smallcaps} L[ISPRO]{.smallcaps} M[IX]{.smallcaps} 25/50 {#sec1-11}
=============================================================================================================================================

As the literature search did not retrieve any observational studies evaluating LM 25, LM 50 is the focus of this section.

The effect of LM 50 tid versus lispro tid plus sulfonylureas (SUs) was evaluated over 24 weeks in an observational, interventional trial of 31 Japanese patients with T2D poorly controlled with submaximal SU doses.\[[@ref72]\] While there was a significant improvement in HbA1c from baseline to week 24 in both treatment groups (*P* \< 0.00001), a similar proportion of patients achieved target HbA1c \<7.0% (LM 50, 67%; prandial--bolus, 69%). Significantly fewer minor HEs occurred with LM 50 versus lispro (0.60 vs. 4.48 episodes/person/year; *P* = 0.03); however, weight gain significantly increased from baseline with the premixed treatment (*P* \< 0.05) but remained unchanged in the comparator group.

C[OMPARATIVE]{.smallcaps} S[TUDIES OF]{.smallcaps} B[IPHASIC]{.smallcaps} I[NSULIN]{.smallcaps} A[SPART]{.smallcaps} 30 [AND]{.smallcaps} L[ISPRO]{.smallcaps} M[IX]{.smallcaps} 25/50 {#sec1-12}
======================================================================================================================================================================================

Despite the breadth of data available for premixed insulin regimens, there are very few data comparing BIAsp 30 with LM 25 or LM 50. Indeed, in the last 15 years (search criteria extended for these data), just three studies have been published comparing these therapies.\[[@ref73][@ref74][@ref75]\]

In an open-label, randomized, single-dose, three-way crossover trial, 61 insulin-treated patients received BIAsp 30, BHI 30 or LM 25 immediately before a test meal.\[[@ref73]\] PPG control assessed by serum glucose excursions 0--5 h postmeal was significantly improved with BIAsp 30 versus BHI 30 and LM 25, with PPG levels 17% lower compared with BHI 30 (16.6 vs. 20.1 mmol/L; *P* \< 0.001) and 10% lower compared with LM 25 (16.6 vs. 18.9 mmol/L; *P* \< 0.05). A total of 53 HEs were reported, most of which were mild. By contrast, a 12-week, open-label, two-period, crossover study in 137 patients who had previously received insulin demonstrated no significant difference between BIAsp 30 bid and LM 25 bid in glycemic control, with treatments providing comparable reductions in HbA1c at week 12.\[[@ref74]\] There were also no significant treatment differences for hypoglycemia (BIAsp 30, 0.69 episodes/month; LM 25, 0.62 episodes/month; *P* = NS). The third study was not a direct comparison of efficacy between BIAsp 30 and LM 25 or LM 50, but a comparison of LM 50 tid compared with progressive titration of LM 25 or BIAsp 30 bid, administered together with metformin.\[[@ref75]\] This 16-week, randomized, parallel-group study of 302 patients failing to achieve glycemic control with BIAsp 30 or LM 25 bid demonstrated no significant treatment difference in mean change from baseline in HbA1c (−1.0% with LM 50 tid, −0.82% with BIAsp 30/LM 25 bid; *P* = NS). While no statistically significant difference was observed between treatments for hypoglycemia, the tid group was associated with greater weight gain than the bid group (1.3 vs. 0.4 kg, respectively; *P* = 0.0009).

There are too few studies to form any conclusions regarding the comparative efficacy and safety of BIAsp 30 and LM 25/LM 50. Whether additional, comparative, studies are required is questionable given that a systematic review of three head-to-head trials of premixed insulin analogs revealed no differences in FPG, PPG, or HbA1c reduction between BIAsp 30, LM 25, and LM 50.\[[@ref76]\]

D[ISCUSSION]{.smallcaps} {#sec1-13}
========================

This review provides an overview of RCTs and observational studies comparing the efficacy and safety of BIAsp 30 and LM 25/LM 50 with other insulin therapies and OADs in patients with T2D. Although BIAsp 50 and BIAsp 70 are available for patients who require more prandial/bolus insulin, BIAsp 30 is the focus of this review given the experience accumulated over the years of use with this formulation. Overall, premixed insulin analogs were associated with improved glycemic control, as evidenced by reductions from baseline in both HbA1c and in PPG versus comparator regimens.\[[@ref31][@ref32][@ref33][@ref34][@ref35][@ref37][@ref42][@ref45][@ref46][@ref48][@ref49][@ref50][@ref51][@ref62][@ref64][@ref65][@ref66][@ref68]\] As such, these data highlight the importance of targeting PPG with an appropriate regimen, and the contribution this makes to the overall achievement of glycemic control. In addition, DURABLE demonstrated long-term treatment with a premixed insulin analog provided modestly improved durability of glycemic control compared with glargine.\[[@ref68]\] In general, however, studies found premixed insulin tended to increase minor hypoglycemia and weight gain compared with basal insulin comparators. While such effects present challenges in T2D, these issues can be managed simply by implementing less aggressive insulin titration schedules, regular meals, and dietary/exercise intervention. Regarding comparisons of the insulin analog BIAsp 30 with BHI 30, the PPG and hypoglycemia benefits observed with the premixed insulin analogs may render them the preferred treatment modality.\[[@ref41][@ref42][@ref45][@ref46]\] This would be especially true in Asia where a large proportion of patients with diabetes are treated with BHI.

In addition to RCTs, large observational trials are beneficial as they investigate the effectiveness and safety of treatments in a real-life setting (i.e. day-to-day clinical practice). Recent findings from the large, observational A~1~ chieve study are particularly noteworthy as they showed that, across four continents, patients with T2D treated with BIAsp 30 achieved improvements from baseline, not only in glycemic control, but also in quality of life.\[[@ref57][@ref58][@ref59][@ref60]\] An improvement in hypoglycemia with BIAsp 30 was also reported in this and other observational trials.\[[@ref54][@ref55][@ref57][@ref58][@ref59][@ref60]\]

The need to individualize treatment regimens is key in many diseases, including T2D, and is illustrated by the results of a *post hoc* analysis of DURABLE. In this analysis, significant differences were observed between race/ethnic groups in the effect of LM 25 and insulin glargine (e.g., smaller reductions in HbA1c for Asian compared with Caucasian patients).\[[@ref71]\] As highlighted in diabetes management guidelines, treatment individualization, focusing on patient preference (including ethnic and cultural needs) is crucial to treatment success.\[[@ref1]\] This is particularly relevant for patients requiring insulin, in terms of when and how to initiate and intensify therapy, and choice of regimen. Another important consideration when initiating and intensifying insulin therapy is the cost of treatment in relation to benefits of glycemic control and the risk of short- and long-term complications. There is evidence that insulin analogs can offer cost-effective treatment, having been associated with improved clinical outcomes and an increase in quality-adjusted life-years.\[[@ref77][@ref78][@ref79][@ref80]\]

Together, these data indicate that premixed insulin regimens are appropriate and convenient treatments for most patients with T2D, offering flexibility in dosing schedule for people with regular eating patterns, and requiring fewer injections compared with basal--bolus regimens. These benefits render premixed insulin analogs the treatment of choice in many Asian countries, including India, where a large proportion of patients are treated in primary care practice.\[[@ref3]\]
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